Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
Search
Advanced search
OR
Browse
Search
Volume 38, Issue 3
Drug Delivery System
Displaying 1-12 of 12 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
FOREWORD
OPINION
[Feature articles] “Application of ionic liquid for Drug Delivery System” Editor:Kotoe Ohta
  • Application of ionic liquids (ILs) and active pharmaceutical ingredients-ILs to overcome biological barriers for drug delivery
    Tatsuya Fukuta, Mayumi Imafuku-Ikeda, Yasunori Iwao
    2023 Volume 38 Issue 3 Pages 190-198
    Published: July 25, 2023
    Released on J-STAGE: October 25, 2023
    DOIhttps://doi.org/10.2745/dds.38.190
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The application of ionic liquids（ILs）to DDS has been investigated to improve physicochemical properties and bioavailability of active pharmaceutical ingredients（APIs）as well as to overcome biological barriers, such as skin and gastrointestinal tract, that hamper drug delivery to the desired site. ILs have been utilized as a drug vehicle to achieve solubilization, stabilization, or enhancement of absorption of APIs. Another approach is converting APIs themselves to ILs, called API-ILs, by using APIs as cationic and/or anionic molecules to prepare ILs. Those approaches can be applied to various therapeutic modalities from small molecular to macromolecular drugs. In this review, we will introduce recent advances on both the use of ILs as drug vehicles and the development of API-ILs, and also summarize their usefulness for drug delivery. Finally, we will introduce our recent work on the development of API-ILs for the treatment of central nervous system diseases.
    View full abstract
    Download PDF (726K)
  • Improvement of Drug Solubility and Stabilization of Polymeric Drugs Using Ionic Liquids
    Takayuki Furuishi, Etsuo Yonemochi
    2023 Volume 38 Issue 3 Pages 199-209
    Published: July 25, 2023
    Released on J-STAGE: October 25, 2023
    DOIhttps://doi.org/10.2745/dds.38.199
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The increasing prevalence of poorly soluble active pharmaceutical ingredients（APIs）in development provides notable risk of new products demonstrating low and erratic bioavailability with consequences for safety and efficacy, particularly for drugs delivered by not only the oral route of administration, but also parenteral administration. In addition, biotechnology has revolutionized science and health care by providing new biomolecules with biological and medical applications. However, the low stability of several life-saving bioproducts still hinders their transport, storage, and application. Herein we summarized recent developments in the area of ionic liquids（ILs）that are being used as improving the solubility of API and stabilizer of protein-based products.
    View full abstract
    Download PDF (1178K)
  • Dissolution and crystallization of API cocrystal using deep eutectic solvent
    Masataka Ito
    2023 Volume 38 Issue 3 Pages 210-219
    Published: July 25, 2023
    Released on J-STAGE: October 25, 2023
    DOIhttps://doi.org/10.2745/dds.38.210
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    A deep eutectic solvent（DES）is a liquid composed of two or more solids or liquids that form hydrogen bonds. DESs are expected to replace organic solvents and have been widely studied for the extraction and synthesis of various substances. In addition, DESs consisting of organic acids and sugars and three-component DESs have been reported in recent years. The authors have prepared DESs that can easily dissolve active pharmaceutical ingredients（APIs）and demonstrated their potential use as solvents for APIs. In particular, the solubility of tadalafil, a poorly water-soluble API, was confirmed to be 24800 times higher than that of water. In addition, a slurry of carbamazepine dispersed in DES containing malonic acid was prepared, and carbamazepine was successfully converted to a co-crystal with malonic acid by bead milling. In this paper, we will discuss the usefulness of DES in alternative solvents and crystallization.
    View full abstract
    Download PDF (706K)
  • Transdermal drug delivery system for biopharmaceuticals using ionic liquids
    Masahiro Goto
    2023 Volume 38 Issue 3 Pages 220-229
    Published: July 25, 2023
    Released on J-STAGE: October 25, 2023
    DOIhttps://doi.org/10.2745/dds.38.220
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The use of ionic liquids as drug delivery systems has received significant attention in recent years, especially due to their ability to enhance transdermal delivery. This function is useful not only for small molecule drugs but also for biopharmaceuticals like peptides and proteins, making it a promising option for developing non-invasive transdermal drug delivery systems. However, it is crucial to ensure the safety of ionic liquids for use as drugs. To address this, we introduce ionic liquids formed from safe materials such as choline, amino acids, fatty acids, and lipids. The use of biocompatible ionic liquids has enabled the development of mid-molecular drugs or transdermal vaccines that exhibit sustained-release properties of DDS. Moreover, there are great expectations for the use of ionic liquids in new modalities such as nucleic acid medicines.
    View full abstract
    Download PDF (879K)
  • Development and medical application of ionic liquid-based transdermal formulations
    Taro Shimizu, Hidetoshi Hamamoto, Tatsuhiro Ishida
    2023 Volume 38 Issue 3 Pages 230-238
    Published: July 25, 2023
    Released on J-STAGE: October 25, 2023
    DOIhttps://doi.org/10.2745/dds.38.230
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Ionic liquids, which are liquid salts at room temperature, attract attention as alternative solvents instead of water and organic solvents. Ionic liquids are composed of organic cation and organic/inorganic anion, and are tuned by combining with various species of ion to obtain desirable characteristics. Application of ionic liquids is currently increasing in medical fields because ionic liquids can increase solubility, stability, and absorption of drugs. Transdermal administration with drugs is non-invasive and convenient approach, while barrier function of the skin limits the absorption of drugs except for hydrophobic small molecular drugs. It has recently reported that the combination of ionic liquids with drugs enables skin permeation of drugs even if the drugs were hydrophilic macromolecules. This suggests that ionic liquids make it possible to treat various types of local and systemic diseases with various drugs, which have never absorbed through the skin barrier. In this review, we introduce the characteristics of ionic liquids used in transdermal drug delivery and application for the several diseases.
    View full abstract
    Download PDF (706K)
  • Application of ionic liquids to intranasal formulation targeting the brain
    Naoto Suzuki
    2023 Volume 38 Issue 3 Pages 239-245
    Published: July 25, 2023
    Released on J-STAGE: October 25, 2023
    DOIhttps://doi.org/10.2745/dds.38.239
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    In developing drugs to treat intractable central nervous system（CNS）diseases, the incidences of which are increasing, there is an urgent need to develop technologies to deliver therapeutic drugs to the brain. The blood-brain barrier（BBB）protects and prevents most orally or intravenously administered drugs from reaching the brain, making it challenging to treat CNS diseases with these drugs. Recently, intranasal administration has attracted attention as a method for delivering therapeutic drugs directly to the brain by bypassing the BBB, as a direct route from the nose to the brain exists. However, mucociliary clearance and nasal mucosal tissue prevent drug absorption from the nasal cavity via this route；therefore, overcoming these issues is essential for efficient drug delivery from the nose to the brain. This article introduces the application of ionic liquids, which have recently attracted attention as materials of drug delivery system in nose-to-brain delivery.
    View full abstract
    Download PDF (755K)
Front line of DDS development in pharmaceutical industries
  • Development of RapifortⓇwipes 2.5％ for the treatment of primary axillary hyperhidrosis
    Mayumi Jitsukawa
    2023 Volume 38 Issue 3 Pages 246-249
    Published: July 25, 2023
    Released on J-STAGE: October 25, 2023
    DOIhttps://doi.org/10.2745/dds.38.246
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    RapifortⓇwipes 2.5％is the first wipe pharmaceutical form approved in Japan and is a partially modified formulation of QbrexzaⓇdeveloped by Dermira, Inc. in January 2022. The wipe is applied to both axillae once a day to control sweating of primary axillary hyperhidrosis. The drug solution impregnated into a wipe is changed to classify it as a non-hazardous substance under the Fire Service Act in Japan. The wipe is selected for reactivity with the drug solution and water absorbency, and the pouch is designed with the multiple-layer structure to ensure drug quality. This article describes the details of the formulation change and packaging design of the wipe and the clinical trial results.
    View full abstract
    Download PDF (454K)
Tips for your DDS research
“Young Square” (mini review)
Meeting Reports
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top